In a nutshell This study examined the effectiveness and safety of isatuximab plus PD (pomalidomide, dexamethasone) for patients with multiple myeloma (MM) that has come back or stopped responding to treatment. This study concluded that isatuximab was well-tolerated and significantly improved survival outcomes for these patients. Some...
Read MoreCurrent disease status-First occurrence of the myeloma Posts on Medivizor
Evaluating intensive CVD chemotherapy for patients with multiple myeloma
In a nutshell This study examined if intensive chemotherapy after initial chemotherapy made treatment more effective for patients with multiple myeloma (MM). The authors concluded that intensive chemotherapy increased survival without tumor growth or spread for these patients. Some background In MM, cancer cells become different...
Read MoreEvaluating lenalidomide-based regimens for elderly patients with multiple myeloma
In a nutshell This study compared different treatment combinations for first-line and maintenance therapies in elderly patients with multiple myeloma (MM). The authors found that first-line MPR was most effective for fit elderly patients, while all patients benefitted from RP maintenance therapy. Some background MM is a complex disease, and...
Read MoreEvaluating the safety and effectiveness of the Shingrix vaccine for patients with blood cancers
In a nutshell This study evaluated the safety and effectiveness of the herpes zoster vaccine (Shingrix) in patients with blood cancer who are receiving anti-cancer therapy. This study concluded that the Shingrix vaccine was effective in these patients, with manageable side effects. Some background Shingles is caused by a virus called herpes zoster....
Read MoreDoes thalidomide improve outcomes for elderly patients with multiple myeloma?
In a nutshell This study evaluated CyBorD (cyclophosphamide, bortezomib, dexamethasone) with or without a switch to another regimen mid-treatment for elderly patients with multiple myeloma (MM). The authors concluded that CyBorD was promising for these patients and that switching to VTD chemotherapy during treatment provided better...
Read MoreComparison between two standard treatments for transplant-ineligible multiple myeloma
In a nutshell This study investigated whether a combination of bortezomib (Velcade), melphalan (Alkeran) and prednisone (Deltasone) was more effective than lenalidomide (Revlimid) and dexamethasone (Decadron) followed by lenalidomide maintenance for newly diagnosed multiple myeloma (MM). The main finding was that age and disease risk influenced the...
Read MoreDoes age influence the safety and effectiveness of stem cell treatment for patients with multiple myeloma?
In a nutshell This study examined the safety and effectiveness of stem cell transplantation (SCT) in elderly patients with multiple myeloma (MM) aged 65 or older compared to younger patients. The authors concluded that SCT was equally as safe and effective for patients in both age groups. Some background Multiple myeloma is a complex type of...
Read MoreExpert recommendations for the treatment of patients with multiple myeloma.
In a nutshell This article provided recommendations for the treatment of patients with multiple myeloma (MM). Some background Multiple myeloma is a type of cancer of the bone marrow that can lead to abnormal immune cells. High-dose chemotherapy followed by a stem cell transplant (SCT) remains a key part of treatment for patients with MM. There are two...
Read MoreA combination of clarithromycin, pomalidomide and dexamethasone in patients with relapsed/unresponsive multiple myeloma
In a nutshell This study aimed to investigate the safety and effectiveness of a combination of clarithromycin, pomalidomide, and dexamethasone (the ClaPd regime) in patients with relapsed/unresponsive multiple myeloma who had been treated with lenalidomide. This study concluded that this combination is as effective as other currently used...
Read MoreEvaluating a treatment combination for patients with newly diagnosed and relapsed multiple myeloma
In a nutshell This study aimed to investigate the combination D-VCd containing daratumumab (Darzalex), bortezomib (Velcade), cyclophosphamide (Cytoxan), and dexamethasone (Decadron) in patients with multiple myeloma. This study concluded that this combination was safe and effective for these patients. Some background...
Read MoreSearching for patients to try a new combination of treatments for multiple myeloma.
In a nutshell This study will investigate the effectiveness of a new combination of chemotherapies: clarithromycin (Biaxin), lenalidomide (Revlimid) and dexamethasone (Decadron), for newly diagnosed multiple myeloma (MM). The main outcome that will be measured is survival without cancer worsening. This trial will take place in New York, the U.S....
Read MoreBortezomib plus lenalidomide for patients with multiple myeloma a after stem cell transplant
In a nutshell This study evaluated the safety and effectiveness of bortezomib (Velcade) and lenalidomide (Revlimid) for patients with multiple myeloma after stem cell transplantation. This study found this combination is effective for these patients, with few side effects. Some background Multiple myeloma (MM) is a type of cancer...
Read More